nrd135s.e1
Small moleculeexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2015 (NCT02345291)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- nrd135s.e1
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05480228 | Phase 2 | Sep 21, 2022 | Harvard University, Icahn School of Medicine at Mount Sinai, National Institute of Neurological Disorders and Stroke (NINDS), New York University |
| NCT02345291 | Phase 2 | Apr 1, 2015 | Novaremed Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 1 | 0 | 1 | 2022 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 0 | 1 | 2022 |
| New York University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Novaremed Ltd. | For profit | 1 | 1 | 1 | 2015 |
5 organizations
Page 1 / 1